A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Condition(s) studied
Investigational drug(s) / intervention(s)
Mosunetuzumab (IV): Participants will receive intravenous (IV) mosunetuzumab.
Mosunetuzumab (SC): Participants will receive subcutaneous (SC) mosunetuzumab.
Polatuzumab vedotin: Participants will receive IV polatuzumab vedotin.
Tocilizumab: Participants will receive IV tocilizumab as needed.
Rituximab: Participants will receive IV rituximab.
Study summary
This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of intravenous (IV) or subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). It will consist of a dose finding portion followed by an expansion phase for second line or later (2L+) participants with relapsed or refractory (R/R) DLBCL and 2L+ R/R FL. In addition, subcutaneous mosunetuzumab in combination with polatuzumab vedotin will be evaluated in participants with at least 2 prior lines of systemic therapy (3L+) for the treatment of R/R mantle cell lymphoma (MCL) and in participants with 2L+ R/R DLBCL.
Eligibility
Primary outcome measure(s)
- Maximum Tolerated Dose (MTD) of Mosunetuzumab in Combination with Polatuzumab Vedotin — Cycle 1 to Cycle 2 (cycle length = 21 days)
- Recommended Phase II Dose of Mosunetuzumab in Combination with Polatuzumab Vedotin — Cycle 1 to Cycle 2 (cycle length = 21 days)
- Percentage of Participants with Adverse Events (AE) — Baseline through approximately 90 days after last study treatment
- Best Objective Response Rate (ORR), Defined as CR or Partial Response (PR) at any Time, Based on PET-CT and/or CT Scan, as Determined by the Independent Review Committee (IRC) using Standard Criteria for NHL — Baseline up to approximately 60 months (assessed at screening and then every 3 months for the first year, then every 6 months until disease progression, start of new anti-cancer therapy, or withdrawal)
Trial sites (29)
| Facility | City | Region | Status |
|---|---|---|---|
| University of Alabama at Birmingham School of Medicine | Birmingham | Alabama | |
| City of Hope | Duarte | California | |
| University of Colorado Hospital - Anschutz Cancer Pavilion | Aurora | Colorado | |
| University of Miami Miller School of Medicine | Miami | Florida | |
| Moffitt Cancer Center | Tampa | Florida | |
| University of Michigan Hospital | Ann Arbor | Michigan | |
| Karmanos Cancer Institute | Detroit | Michigan | |
| New York University Langone Medical Center | New York | New York | |
| Levine Cancer Institute | Charlotte | North Carolina | |
| Penn State Milton S. Hershey Medical Center | Hershey | Pennsylvania | |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | |
| University of Pittsburgh - Hillman Cancer Center | Pittsburgh | Pennsylvania | |
| Lifespan Cancer Institute | Providence | Rhode Island | |
| University of Texas M.D. Anderson Cancer Center | Houston | Texas | |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | |
| Medical College of Wisconsin, Froedtert Hospital;Nephrology Section | Milwaukee | Wisconsin | |
| UZ Brussel | Brussels | Belgium | |
| CH Jolimont - Lobbes (Jolimont) | Haine-Saint-Paul | Belgium | |
| Clinique St Pierre asbl | Ottignies | Belgium | |
| Hamilton Health Sciences - Juravinski Cancer Centre | Hamilton | Ontario | |
| Jewish General Hospital | Montreal | Quebec | |
| Saskatchewan Cancer Agency (SCA) - Saskatoon Cancer Centre (SCC) | Saskatoon | Saskatchewan | |
| Institut Catala d Oncologia Hospital Duran i Reynals | Barcelona | Spain | |
| Hospital de San Pedro de Alcantara | Cáceres | Spain | |
| Hospital General Universitario Gregorio Marañon | Madrid | Spain | |
| Hospital Infanta Leonor; Servicio de Hematologia | Madrid | Spain | |
| Hospital Universitario Virgen Macarena; Servicio de Oncologia | Seville | Spain | |
| Cambridge University Hospitals NHS Foundation Trust | Cambridge | United Kingdom | |
| Plymouth Hospitals NHS Trust; Pharmacy Dept | Plymouth | United Kingdom |
More Hoffmann-La Roche trials in Canada
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03671018 on ClinicalTrials.gov ↗ ← All trials in Canada